The life sciences industry is competitive, volatile, and constantly changing—three reasons the Securities and Exchange Commission (SEC) scrutinizes life sciences companies’ pre- and post-IPO filings.
Streamline your company’s filing process by reviewing our annual report, Under the Microscope: An Analysis of SEC Comment Letter Trends Among Middle-Market and Pre-IPO Life Sciences Companies.
The in-depth report takes a look at SEC comment letter trends directed toward S-1, 10-K, 10-Q, and 20-F filings; comparisons to prior years; and implications for your middle market or pre-IPO life sciences company.